SINEMET
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SINEMET (SINEMET).
Sinemet is a combination of carbidopa and levodopa. Levodopa is converted to dopamine in the brain, replenishing depleted dopamine levels in the striatum, thereby improving motor symptoms of Parkinson's disease. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing levodopa's central availability and reducing peripheral side effects.
| Metabolism | Levodopa is extensively metabolized by aromatic L-amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) primarily in the periphery and central nervous system. Carbidopa inhibits peripheral AAAD but does not cross the blood-brain barrier. Levodopa is also metabolized by monoamine oxidase (MAO) pathways, but this is minor. Approximately 70-80% of levodopa is converted to dopamine metabolites. |
| Excretion | Renal: 70-80% as metabolites (including 3-O-methyldopa and homovanillic acid), <10% unchanged. Biliary/fecal: <5%. |
| Half-life | Carbidopa: 1-2 hours. Levodopa: 1-3 hours (terminal half-life ~2 hours). Clinical context: short half-life necessitates frequent dosing (typically 3-4 times daily) to maintain therapeutic levels. |
| Protein binding | Levodopa: <10% (negligible). Carbidopa: ~36% (primarily to albumin). |
| Volume of Distribution | Levodopa: 0.9-1.6 L/kg (extensively distributed, crosses blood-brain barrier). Carbidopa: limited distribution (does not cross BBB). |
| Bioavailability | Oral (levodopa): 20-30% when coadministered with carbidopa (carbidopa inhibits peripheral dopa decarboxylase, increasing bioavailability). Oral (carbidopa): 40-70%. |
| Onset of Action | Oral: 30-60 minutes (first measurable effect). Peak effect at 1-2 hours. |
| Duration of Action | 3-6 hours (clinical response corresponds to levodopa plasma levels; motor fluctuations may occur with chronic use). |
| Brand Substitutes | Duodopa 250mg/25mg Tablet, Levopa C 250mg/25mg Tablet, Syndopa Forte Tablet, Syndopa 275 Tablet, Tidomet Forte Tablet |
Carbidopa/levodopa 25/100 mg, one tablet orally three times daily, titrated to maximum of 8 tablets per day (200 mg carbidopa/2000 mg levodopa) in divided doses.
| Dosage form | TABLET |
| Renal impairment | GFR 30-89 mL/min: No adjustment recommended; GFR 15-29 mL/min: Use with caution, reduce dose by 50%; GFR <15 mL/min: Contraindicated. |
| Liver impairment | Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 50%; Child-Pugh C: Contraindicated. |
| Pediatric use | Weight-based: Not approved for pediatric use (safety and efficacy not established). |
| Geriatric use | Initiate with lowest effective dose (e.g., carbidopa/levodopa 25/100 mg once or twice daily); titrate slowly due to increased risk of orthostatic hypotension, falls, and cognitive effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SINEMET (SINEMET).
| Breastfeeding | Levodopa is excreted in human milk (M/P ratio not reported). Use caution; may inhibit lactation due to prolactin suppression. Avoid breastfeeding or monitor infant for adverse effects such as hypotonia or poor feeding. |
| Teratogenic Risk | FDA Pregnancy Category C. In the first trimester, studies in animals have shown adverse effects (visceral and skeletal malformations) at doses similar to human doses; human data are insufficient. In the second and third trimesters, carbidopa/levodopa may be associated with increased risk of gestational hypertension and preterm labor. No definitive human teratogenicity established, but use only if benefit outweighs risk. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Concurrent use of non-selective monoamine oxidase (MAO) inhibitors","Narrow-angle glaucoma","Known hypersensitivity to any component of the formulation","Suspicious undiagnosed skin lesions (history of melanoma)"]
| Precautions | ["May cause or exacerbate dyskinesias","Risk of falling asleep during daily activities, including driving","May cause hallucinations and psychosis-like behavior","May cause impulse control disorders (e.g., pathological gambling, hypersexuality)","Cardiovascular effects: hypotension, cardiac arrhythmias","May cause melanoma; monitor skin lesions","Neuroleptic malignant syndrome-like symptoms upon abrupt dose reduction or withdrawal","May cause elevated liver enzymes, hepatitis, or jaundice","Potential for drug interactions with MAO inhibitors (avoid concomitant use within 14 days)"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, signs of gestational hypertension, and uterine activity. Assess fetal growth and well-being via ultrasound and non-stress tests. Monitor for potential exacerbation of maternal symptoms (e.g., dyskinesias, psychiatric effects). |
| Fertility Effects | No direct evidence of impaired fertility in humans. In animal studies, carbidopa/levodopa has not shown adverse effects on fertility. However, hyperprolactinemia from other dopaminergic agents can affect ovulation; levodopa may reduce prolactin levels. |